妊娠期糖尿病管理前后过度体重增加的影响
该研究前瞻性分析3281例妊娠期糖尿病孕妇,发现23.6%在首次就诊时已存在过度妊娠期体重增加(EGWG)。EGWG与更高的空腹血糖、更频繁的胰岛素治疗相关;管理期间持续EGWG每增加2kg,胰岛素使用风险增加1.3倍,最终日胰岛素剂量增加8单位,大于胎龄儿风险增加1.4倍。
要点
- GDM管理前已存在EGWG者空腹血糖更高且更需胰岛素治疗。
- 管理期间持续EGWG每增2kg,胰岛素用量及大于胎龄儿风险显著增加。
- 避免EGWG及限制持续EGWG可能改善GDM母婴结局。
核心结论
- 无EGWG及限制持续EGWG对基于oGTT的空腹血糖、大于胎龄儿风险和胰岛素需求有缓解作用。
研究设计与样本
- 前瞻性队列研究,纳入单中心3281例妊娠期糖尿病孕妇,依据1998年澳大利亚妊娠糖尿病学会指南诊断。
主要发现
- 776例(23.6%)存在EGWG。
- EGWG组平均空腹血糖为5.2 mmol/L(95%CI 5.1-5.3),非EGWG组为5.0 mmol/L(95%CI 4.9-5.0),P<0.01。
- EGWG组胰岛素治疗比例47.0% vs 33.6%,P<0.0001,校正后OR 1.4(95%CI 1.1-1.7,P<0.01)。
- 持续EGWG每增加2kg,胰岛素治疗aOR 1.3(95%CI 1.1-1.5,P<0.001),最终日胰岛素剂量增加8单位(95%CI 5.4-11.0,P<0.0001),大于胎龄儿风险aOR 1.4(95%CI 1.2-1.7,P<0.0001)。
临床怎么用
- GDM管理应同时关注体重增加,而不仅优化血糖。
- 对已存在EGWG者应加强干预以限制持续体重增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Conventional gestational diabetes mellitus (GDM) management focuses on managing blood glucose in order to prevent adverse outcomes. We hypothesized that excessive weight gain at first presentation with GDM (excessive gestational weight gain [EGWG]) and continued EGWG (cEGWG) after commencing GDM management would increase the risk of adverse outcomes, despite treatment to optimize glycemia. RESEARCH DESIGN AND METHODS: Data collected prospectively from pregnant women with GDM at a single institution were analyzed. GDM was diagnosed on the basis of Australasian Diabetes in Pregnancy Society 1998 guidelines (1992-2015). EGWG means having exceeded the upper limit of the Institute of Medicine-recommended target ranges for the entire pregnancy, by GDM presentation. The relationship between EGWG and antenatal 75-g oral glucose tolerance test (oGTT) values and adverse outcomes was evaluated. Relationships were examined between cEGWG, insulin requirements, and large-for-gestational-age (LGA) infants. RESULTS: Of 3,281 pregnant women, 776 (23.6%) had EGWG. Women with EGWG had higher mean fasting plasma glucose (FPG) on oGTT (5.2 mmol/L [95% CI 5.1-5.3] vs. 5.0 mmol/L [95% CI 4.9-5.0]; P < 0.01), after adjusting for confounders, and more often received insulin therapy (47.0% vs. 33.6%; P < 0.0001), with an adjusted odds ratio (aOR) of 1.4 (95% CI 1.1-1.7; P < 0.01). aORs for each 2-kg increment of cEGWG were a 1.3-fold higher use of insulin therapy (95% CI 1.1-1.5; P < 0.001), an 8-unit increase in final daily insulin dose (95% CI 5.4-11.0; P < 0.0001), and a 1.4-fold increase in the rate of delivery of LGA infants (95% CI 1.2-1.7; P < 0.0001). CONCLUSIONS: The absence of EGWG and restricting cEGWG in GDM have a mitigating effect on oGTT-based FPG, the risk of having an LGA infant, and insulin requirements.
引用
- Barnes RA, Wong T, Ross GP, et al. Excessive Weight Gain Before and During Gestational Diabetes Mellitus Management: What Is the Impact? Diabetes Care. 2019. PMID: 31690637. doi:10.2337/dc19-0800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。